Bayer AG
393 articles about Bayer AG
-
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
3/20/2024
Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.
-
Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing
3/19/2024
Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd., announced that it is extending its joint validation trials for its biofungicides conducted by Bayer AG, a global leader in the agriculture industry, after successful first-year laboratory and greenhouse testing.
-
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure
2/16/2024
Bayer AG and Asklepios BioPharmaceutical, Inc. announced that the first patient has been randomized in GenePHIT, a Phase II trial of AB-1002 for the treatment of congestive heart failure.
-
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
2/6/2024
Vividion Therapeutics, Inc., announced that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors.
-
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
1/23/2024
BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced today that it has exercised its option to exclusively license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for the treatment of primary photoreceptor diseases, from FUJIFILM Cellular Dynamics and Opsis Therapeutics.
-
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
1/4/2024
Recursion announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’ fibrosis research collaboration.
-
AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions
11/12/2023
Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, presented first-in-human data from a Phase 1 trial investigating AB-1002 for the treatment of patients with congestive heart failure at this year's American Heart Association Scientific Sessions, which are being held in Philadelphia, U.S., from November 11 to 13, 2023.3,4
-
Bayer to Partner With Twist Bioscience to Accelerate Drug Discovery
10/5/2023
Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform.
-
Vividion Therapeutics Names Shawn Rose as Chief Development Officer
9/7/2023
Vividion Therapeutics, Inc. and a wholly owned and independently operated subsidiary of Bayer AG, announced that Dr. Shawn Rose, M.D. Ph.D., has joined the company as Chief Development Officer, Immunology, reporting to our Chief Executive Officer, Aleksandra Rizo.
-
Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas Therapeutics
6/6/2023
Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle delivery systems for molecular therapeutics.
-
AskBio Co-Founder Jude Samulski Receives Inaugural European Society of Gene and Cell Therapy Founders Award
10/28/2022
Asklepios BioPharmaceutical, Inc. announced that R. Jude Samulski, Ph.D., AskBio President, Co-Founder and Chief Scientific Officer, received the inaugural European Society of Gene and Cell Therapy Founders Award in Edinburgh, Scotland, during the recent ESGCT 29th Congress.
-
Bayer’s Vividion Emerging as Significant Player in San Diego Biotech Hub
6/9/2022
Innovative business model preserves Vividion’s entrepreneurial culture and pipeline focus, while adding the technical expertise and resources of a global pharma leader.
-
AskBio President of Therapeutics Dr. Katherine High receives Award from American Society of Gene and Cell Therapy
5/23/2022
Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, announced that Dr. Katherine High, President of Therapeutics, received the Jerry Mendell award for Translational Science from the American Society of Gene and Cell Therapy.
-
Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam
2/16/2022
Organon announced that it has acquired the rights from Bayer AG to Marvelon® and Mercilon®, combined oral hormonal daily contraceptive pills, in the People’s Republic of China, including Hong Kong and Macau, and has entered into an agreement to acquire the rights to these products in Vietnam.
-
AskBio and Touchlight Restructure Joint Venture
2/8/2022
Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, and Touchlight, a biotechnology company pioneering enzymatic DNA production, have announced a revised structure to their former joint venture, Touchlight AAV.
-
Leaps by Bayer Leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing
1/25/2022
Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, today announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG —Leaps by Bayer— 8VC, and Humboldt Fund.
-
Cellino is a closed loop cell therapy manufacturing company that aims to make stem cell-based regenerative therapies available to all eligible patients and researchers using cells in clinical research.
-
Celmatix Achieves Milestone for PCOS Drug Program
1/18/2022
Celmatix Inc., a biotechnology company focused on ovarian biology, announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec.
-
Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology
1/10/2022
Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.
-
The cash came rolling in for four biopharma companies Thursday morning, with collective Series A rounds totaling more than $125 million.